Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that includes hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia. Due to the high prevalence (around 1/3 of the world population) economic burden of MetS, there is a need for new dietary, lifestyle, and therapeutic options. Recently, fasting emerged as a dietary method proposed for controlling metabolic risk factors. Intermittent fasting (IF), or time-restricted feeding (TRF), describes an array of feeding patterns in which calorie intake is restricted to a specific time period. Hence, this review aimed to elucidate the latest data on MetS and explore the viability of simple management options, such as IF and TRF. Preclinical studies have shown how IF/TRF exerts beneficial effects on the gut microbiota, glucose and insulin metabolism, weight and visceral fat, and lipid metabolism. However, the results obtained from human studies are somewhat conflicting, as weight loss was achieved in all studies, whereas in some studies, there was no significant effect on insulin resistance, cholesterol/lipid metabolism, or blood pressure. Nevertheless, as only very few human studies were performed, there is a need for more randomized control trials on larger cohorts of patients with MetS to gather higher-yield evidence to clarify whether IF/TRF are suitable dietary patterns for this population.

Details

Title
Can Fasting Curb the Metabolic Syndrome Epidemic?
Author
Vrdoljak, Josip 1 ; Kumric, Marko 1   VIAFID ORCID Logo  ; Marino Vilovic 1   VIAFID ORCID Logo  ; Martinovic, Dinko 1   VIAFID ORCID Logo  ; Rogosic, Veljko 2 ; Borovac, Josip A 3   VIAFID ORCID Logo  ; Kurir, Tina Ticinovic 4 ; Bozic, Josko 1   VIAFID ORCID Logo 

 Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia; [email protected] (J.V.); [email protected] (M.K.); [email protected] (M.V.); [email protected] (D.M.); [email protected] (J.A.B.); [email protected] (T.T.K.) 
 Department of Ophthalmology, University of Split School of Medicine, 21000 Split, Croatia; [email protected]; Department of Ophthalmology, University Hospital of Split, 21000 Split, Croatia 
 Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia; [email protected] (J.V.); [email protected] (M.K.); [email protected] (M.V.); [email protected] (D.M.); [email protected] (J.A.B.); [email protected] (T.T.K.); Department of Health Studies, University of Split, 21000 Split, Croatia; Department of Cardiology, University Hospital of Split, 21000 Split, Croatia 
 Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia; [email protected] (J.V.); [email protected] (M.K.); [email protected] (M.V.); [email protected] (D.M.); [email protected] (J.A.B.); [email protected] (T.T.K.); Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Split, 21000 Split, Croatia 
First page
456
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20726643
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2627825352
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.